Divi's Laboratories — Q1 FY26
Divis Laboratories reported a strong Q1 FY26 with PAT rising 26.7% YoY to INR 545 crore, driven by robust custom synthesis traction and backward integration benefits.
bullish
medium
✓ Verified against BSE filing
Indian management teams deliver on roughly 12% of specific earnings-call promises. A low score does not indicate dishonesty — it reflects how aspirational forward guidance typically is.
Q4 FY25
Double-digit revenue growth in FY26
Management expects overall revenue to grow at a double-digit rate in FY26, driven by custom synthesis and generics.
Missed
Current-quarter commentary contains related risk or weakness, so the promise appears not to have been delivered yet.
heuristic_v1